BrainStorm Cell Therapeutics, Appoints Renowned Neurologists Prof. Warren Olanow and Prof. Andre Lozano to Scientific Advisory Board; Completes Formation of Scientific Advisory Board

Business Wire, April 27, 2005

NEW YORK & TEL AVIV, Israel -- BrainStorm Cell Therapeutics (OTCBB:BCLI), an emerging company in stem cell therapeutics for neurological diseases, today announced that Prof. Andre Lozano and Prof. C. Warren Olanow, internationally renowned clinical neurologists and researchers, have been appointed to the Company's Scientific Advisory Board.

"We are very excited that medical researchers of the stature of Prof. Olanow and Prof. Lozano are joining us in our journey to develop solutions for neurodegeneration. Their authoritative clinical expertise combined with their cutting-edge research achievements will be a tremendous source of guidance to BrainStorm. Their appointments complete the formation of our Scientific Advisory Board which also includes the world class clinicians and scientists, Prof Eldad Melamed, Prof Jeffrey Kordower and Prof. Ole Isacson. We believe that this outstanding team of advisors will provide us with significant value as we move ahead to develop therapies for Parkinson's and other diseases," said Yaffa Beck, CEO.

Prof. Warren Olanow, M.D. FRCPC is the Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology and Professor of Neuroscience at the Mount Sinai School of Medicine in New York City. He is also the Chief of the Neurology Service at the Mount Sinai Hospital.

He served on the faculties of McGill University, Duke University, and the University of South Florida prior to assuming his present position. Prof. Olanow has authored more than 300 publications primarily related to Parkinson's disease and neurodegeneration. He is Treasurer of the American Neurological Association and was previously President of the Movement Disorder Society and the International Society of Motor Disturbances. He has been named an Honorary Professor at the University of London (Royal Free Hospital) and an Honorary Member of the French Neurological Society. He has served on numerous editorial and scientific advisory boards and has lectured at Universities and Conferences throughout the world.

Prof. Lozano currently holds the RR Tasker Chair in Functional Neurosurgery and a Canada Research Chair in Neuroscience at the University of Toronto. He also serves as Head of Applied and Interventional Research at the Toronto Western Research Institute.

Prof. Lozano's research is focused on understanding the cellular pathogenesis and developing novel treatments, including surgical therapies, for neurological disorders such as Parkinson's disease and dystonia. His work has appeared in over 200 publications and he has been invited lecturer or visiting professor in North and South America, Europe, Asia, Africa and Australia. He serves on the board and executive of several international organizations and is currently President of the American Society for Stereotactic and Functional Neurosurgery and Chair of the Stereotactic and Functional Neurosurgery section of the World Federation of Neurosurgery. He serves the international editorial board of several journals and is Associate Editor of the Canadian Journal of Neurological Sciences. He has received a number of awards including the Gold Medal of the Royal College of Physicians and Surgeons of Canada and the Penfield Award.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like stem cell therapeutic products, NurOwn(TM), based on autologous bone marrow derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM) patent pending technology is based on discoveries made by the team of prominent neurologist, Prof. Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University, enabling the differentiation of bone marrow derived stem cells into functional neurons, as demonstrated in animal models. The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University. The company's initial focus is on developing treatments for Parkinson's Disease.

About Stem Cell Therapy

Stem cells are non-specialized cells with a remarkable potential for both self-renewal and differentiation into cell types with a specialized function, such as muscle, blood or brain cells. Stem cells may be sourced from fetal or embryonic tissue or from adult tissue reservoirs such as bone marrow. Use of embryonic stem cells, has become the center of significant ethical and moral debate. In contrast, use of adult stem cells does not face the same moral or legal controversy. Stem cell therapy aims to "cure" disease by replacing the 'diseased' cells with 'healthy' cells derived from stem cells. This approach has the potential to revolutionize medicine and, if successful, the implied commercial opportunities are great. Currently, both embryonic stem cells (ESC) and adult stem cells (ASC) are being explored as the potential basis for multiple cell therapy products.